Skip to main content
TipRanks
Go Ultimate75% OFF

RegenXBio (RB0) AI Stock Analysis

1 Followers
DE:RB0

RegenXBio

(Frankfurt:RB0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
AAV platform and partnershipsREGENXBIO combines an AAV technology platform with internal programs and partner arrangements, creating multiple routes to future revenue. Licensing, milestones, royalties and collaboration payments can diversify commercialization outcomes while extending the platform’s strategic value across serious genetic diseases.
Negative Factors
Persistent losses and cash burnSubstantial operating and free-cash-flow deficits show that the current business is consuming capital rather than funding development internally. Continued losses increase dependence on existing liquidity, future financing or partner payments, while potentially limiting flexibility if clinical timelines extend or outcomes disappoint.

RegenXBio (RB0) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%60%DE:RB0-22.37%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 505.18M
Dividend Yield
―
Average Volume (3M)
1,604
Price to Earnings (P/E)
-2.4
Beta (1Y)
1.46
Revenue Growth
-10.99%
EPS Growth
10.99%
Country
Germany
Employees
371
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

RegenXBio Business Overview & Revenue Model

Company Description

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the...

RegenXBio Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:7.17%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly optimistic, with extensive progress across sura-vec and RGX-202, encouraging clinical and biomarker data, significant AbbVie milestone funding, a cash runway extending beyond late 2027 milestones, and preparations for potential commercialization. The principal negatives were the unresolved regulatory path for RGX-121, the expiration of U.S. ZOLGENSMA intellectual property, and the fact that major sura-vec and RGX-202 regulatory milestones remain pending.

Positive Updates

Multiple Potential Regulatory Milestones and Commercial Preparation
REGENXBIO is approaching multiple potential regulatory approvals and preparing for commercialization. Sura-vec top-line data from the ATMOSPHERE and ASCENT pivotal studies are expected this quarter, global regulatory submissions are expected in 2027, and RGX-202 is advancing toward a potential BLA submission in the first quarter of 2027.

Negative Updates

RGX-121 Path Forward Remains Undetermined
For RGX-121, the company continues to collect and evaluate additional patient imaging and long-term follow-up data. REGENXBIO is working with the FDA and NS Pharma but has not yet provided a defined regulatory path and said it will update investors as the program progresses.

Company Guidance

REGENXBIO expects top line results from both ATMOSPHERE and ASCENT this quarter, followed by global regulatory submissions in 2027; RGX-202 preparations are underway for a full BLA submission in the first quarter of 2027 under the accelerated approval pathway, supporting potential approval in the U.S. in the second half of 2027, while the AFFINITY RISE study is expected to initiate in the first half of 2027 and enroll approximately 100 patients with a 2:1 active to placebo randomization. The company expects its RGX-202 BLA to include safety data from more than 60 patients, expects pre-BLA meeting minutes about 30 days post the meeting, expects BLA acceptance about 2 months after submission, and expects a review process through the next 6 months. For wet AMD, the goal is at least a 50% reduction in treatment burden with a meaningful proportion of those patients not needing any injection, and cash runway is late into fourth quarter of 2027.

RegenXBio Risk Analysis

RegenXBio disclosed 54 risk factors in its most recent earnings report. RegenXBio reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

RegenXBio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:RB0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IRDIRD53Neutral$384.68M-2.609999.00%―-45.92%10.87%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FDMTFDMT45Neutral$675.64M-4.38-47.06%―79952.50%29.07%
RCKTRCKT42Neutral$256.82M-16.43-5.34%――93.49%
SLDBSLDB42Neutral$763.42M-3.82-67.78%――28.59%
NGNENGNE39Underperform$495.37M-4.30-44.36%――-25.59%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:RB0IRDNGNERCKTSLDBFDMTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:RB0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:RB0RegenXBio Inc.7.14-2.76-27.86%
IRDOpus Genetics, Inc.3.982.24128.74%
NGNENeurogene Inc.23.931.476.54%
RCKTRocket Pharma2.30-0.74-24.34%
SLDBSolid Biosciences6.842.5057.60%
FDMT4D Molecular Therapeutics, Inc.12.231.2811.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.